ALS drug engensis passes safety check in small extension study
NCT ID NCT05176093
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This study looked at the long-term safety of a drug called Engensis in 8 people with ALS who had already received it in a previous study. Researchers monitored side effects over 6 months. The goal was to see if repeated doses remain safe, not to measure if the drug slows or stops the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Neuromuscular Center
Austin, Texas, 78759, United States
-
Hanyang University Medical Center
Seoul, 04763, South Korea
Conditions
Explore the condition pages connected to this study.